CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

Inclusion Criteria:

Participants are eligible to be included in the study only if all the following criteria apply:

1. Females ≥18 years of age (or the legal age of consent in the jurisdiction in whichthe study is taking place) at the time of signing the informed consent.

2. Participants must sign the informed consent, which includes compliance with therequirements and restrictions listed in the informed consent form (ICF) and in thisprotocol.

3. Disease Type:

• Histologically or cytologically confirmed diagnosis of advanced (unresectable)or metastatic high grade serous ovarian, primary peritoneal (i.e, of primaryorigin), or fallopian tube cancer. High-grade endometrioid ovarian cancer ispermitted for enrollment.

• Participant's tumor must be positive for CLDN6 expression as defined by theCLDN6 reference laboratory assay. Tumor tissue will be required for submissionfor CLDN6 testing prior to Cycle 1 Day 1.

• Participants must have platinum-resistant disease, defined as the following:

• If participants received only 1 line of platinum-based therapy, they must havecompleted 4 or more cycles of platinum-containing therapy, must have achieved aCR or PR, and progressed >3 months but ≤6 months after the last dose ofplatinum.

• Participants who have received more than 1 line of platinum- based therapy musthave progressed on or within 6 months after the last dose of platinum.

• NOTE: This should be calculated from the date of the last administered dose ofplatinum therapy to the date of the radiographic imaging showing progression (per RECIST v1.1).

• Participants who are platinum-refractory during front-line treatment areexcluded.

• Participants must have received at least 1 but no more than 3 prior systemiclines of anticancer therapy, and for whom single- agent therapy is appropriateas the next line of treatment. Study rules for evaluation of number of priorsystemic lines of therapy:

• Adjuvant ± neoadjuvant is considered one line of therapy

• Maintenance therapy (eg, bevacizumab or PARP inhibitors) will be consideredpart of the preceding line of therapy (ie, not counted independently)

• Therapy changed due to toxicity in the absence of progression will beconsidered part of the same line (ie, not counted independently)

• Hormonal therapy will not be counted as a separate line of therapy

4. Measurable disease, per RECIST v1.1

5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1.

6. Adequate organ function, based on the following laboratory values:

• ANC: ≥1,500/mcL

• Platelets: ≥100,000/mcL without transfusion within 4 weeks of first dose

• Hemoglobin: 9 g/dL with transfusion or EPO support up to 14 days beforeeligibility assessment

• Measured or calculated creatinine clearance with a validated formula*: ≥30mL/min

• Serum total bilirubin: ≤1.5 X ULN (participants with known Gilbert disease orliver metastases who have serum bilirubin level ≤3×ULN may be enrolled

• AST (SGOT) and ALT (SGPT): ≤3 X ULN (participants with active liver metastaseswho have ALT/AST ≤5 X ULN may be enrolled)

• Albumin: ≥2.5 g/dL

• ECG: 12-Lead ECG with normal tracing or non-clinically significant changes thatdo not require medical intervention and QTcF interval

• 470 msec and without history of Torsades des Pointes or other symptomaticQTc abnormality.

7. Participants of childbearing potential must have a negative serum pregnancy testwithin 72 hours before starting study drug treatment. The serum pregnancy test mustbe negative for the participant to be eligible.

8. Participants must agree to use a highly effective birth control method from the timeof the first study drug treatment through 7 months after the last study drugtreatment, or be of nonchildbearing potential.

9. Participants must agree not to donate eggs from the first study drug treatmentthrough 7 months after the last study drug treatment.

10. Participants must agree to not breastfeed from the first dose of study treatmentthrough 90 days after the last dose of study treatment.

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

1. Has not recovered [recovery is defined as National Cancer Institute CommonTerminology Criteria for Adverse Events (NCI CTCAE), version 5.0, Grade ≤1] from theacute toxicities of previous therapy, except treatment-related alopecia orlaboratory abnormalities otherwise meeting eligibility requirements.

2. Participants with clear cell, mucinous, sarcomatous (including carcinosarcoma),mixed histology, or low-grade, borderline ovarian tumors or non-epithelial ovariancancers.

3. Participants with primary platinum-refractory ovarian, primary peritoneal (i.e. ofprimary origin) or fallopian tube cancer, defined as disease that did not respond toor has progressed within 3 months of the last dose of first line platinum-containingchemotherapy.

4. Received prior chemotherapeutic, investigational, radiotherapy, or other therapiesfor the treatment of cancer within 14 days with small molecule and within 28 dayswith biologic before the first dose of TORL-1-23. There is no waiting periodrequired for stereotactic radiosurgery.

5. Prior treatment with a CLDN6-targeting agent or an MMAE-containing ADC.

6. Progressive or symptomatic brain metastases. Brain metastases that have beenradiated, are asymptomatic, and on a stable or decreasing dose of steroids areallowed. Leptomeningeal disease is excluded.

7. Grade 2 or greater peripheral neuropathy.

8. History of non-infectious pneumonitis/ILD within 6 months of first dose of studydrug.

9. Participants must not be considered a high medical risk due to a serious,uncontrolled medical disorder, nonmalignant systemic disease, or active,uncontrolled infection. Examples include, but are not limited to, uncontrolled majorseizure disorder, unstable spinal cord compression, superior vena cava syndrome, orany psychiatric disorder that prohibits obtaining informed consent.

10. History of significant cardiac disease:

11. Congestive heart failure >New York Heart Association class 2 within last year

12. Unstable angina (angina symptoms at rest), new-onset angina (begun within thelast 3 months)

13. Myocardial infarction less than 6 months before start of study drug

14. Anti-arrhythmic therapy (beta blockers are permitted)

15. Any unstable ischemic disease or untreated arrhythmia

16. Known history of myelodysplastic syndrome or acute myeloid leukemia.

17. History of another cancer within 3 years before Day 1 of study treatment, with theexception of basal or squamous cell carcinoma of the skin that has been definitivelytreated. Participants with malignancies with a low risk of recurrence, includingappropriately treated ductal carcinoma in situ of the breast are not excluded.

18. Uncontrolled infection; active, clinically serious infections (CTCAE Grade >2).

19. Participants with seizure disorder requiring medication.

20. Known hypersensitivity or intolerance to any of the study drugs, study drug classes,or excipients in the formulation.

21. History of having an allogeneic bone marrow or organ transplant.

22. Any condition (concurrent disease, infection, or comorbidity) that interferes withability to participate in the study, causes undue risk, or complicates theinterpretation of safety data, in the opinion of the Investigator.

23. Participants who are taking any drugs that are strong inducers and/or stronginhibitors of CYP3A4 enzymes.

24. Participants who are taking any drugs that are inhibitors of P-glycoprotein.